The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana, India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies, Telangana, at Hyderabad.
2020
-Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1.
2021
-CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology
transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG.
2022
-Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family.
-Suven Pharmaceuticals approves acquisition of Casper Pharma.
2023
--Advent International announces the completion of the acquisition of Suven Pharma"".
--Suven Pharma to manufacture anti-covid drugs Molnupiravir and 2-DG
2024
-Amalgamation of Casper Pharma Pvt Ltd (WOS) into and with Suven Pharmaceuticals Ltd'
-The company has informed that Record date for the purpose of Merger/HiveOff is 08-May-2025.
2025
-Company name has changed to Cohance Lifesciences Ltd. from Suven Pharmaceuticals Ltd..
|